Literature DB >> 21030917

Surgical treatment of metachronous nonsmall cell lung cancer.

Shuji Haraguchi1, Kiyoshi Koizumi, Tomomi Hirata, Kyoji Hirai, Iwao Mikami, Hirotoshi Kubokura, Yuki Nakajima, Kazuo Shimizu.   

Abstract

PURPOSE: We report surgical results of metachronous nonsmall cell lung cancer (NSCLC).
METHODS: We report mortality and analyze prognostic factors for overall survival in patients with metachronous NSCLC at Nippon Medical School from July 1982 to July 2008.
RESULTS: Thirty-three out of 1726 patients (1.9%) who underwent lung resection had metachronous NSCLC. Mortality rate was 10%. On univariate analyses, the different histologies at the first and second operations were the only significant poor prognostic factor. Twenty-two patients (73%) had the same histology at the first and second operations: adenocarcinoma in 18 (60%) and squamous cell carcinoma in 4 (13%). Their actuarial 5- and 10-year overall survivals were both 71%, compared to 47% and 16% for patients with different histology (p = 0.0174). Sex (p = 0.1742), locations of the first and second cancers (p = 0.3957), operative procedures in patients with p-stage I at the second operation (p = 0.2782), pathological stage at the first operation (p = 0.5958), and pathological stage at the second operation (p = 0.0609) were not prognostic factors. Different histology at the first and second operations was significant based on a multivariate analysis (Hazard ratio: 3.918; p value: 0.0269; 95% confidence interval: 1.169-13.131). The actuarial 5- and 10-year overall survivals for the first cancer was 86% and 64%, compared to 65% and 45% for the second (p = 0.0609).
CONCLUSIONS: Our study shows that a surgical approach is beneficial for patients with metachronous NSCLC. Good prognosis in patients with the same histology may support the current criteria of metachronous NSCLC mainly based on the histology.

Entities:  

Mesh:

Year:  2010        PMID: 21030917

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  8 in total

1.  Extremely Didactic Experience About the Postoperative Recurrence of Lung Cancer: a Case Report.

Authors:  Taiji Kuwata; Akihiro Taira; Yusuke Nabe; Shuichi Shinohara; Fumihiro Tanaka
Journal:  Indian J Surg Oncol       Date:  2018-04-30

2.  Metachronous second primary lung cancer surgically treated five years or more after the initial surgery.

Authors:  Satoshi Koezuka; Yoshinobu Hata; Hajime Otsuka; Takashi Makino; Naobumi Tochigi; Kazutoshi Shibuya; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2015-07-01

3.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

4.  Predictors of imaging surveillance for surgically treated early-stage lung cancer.

Authors:  Leah M Backhus; Farhood Farjah; Steven B Zeliadt; Thomas K Varghese; Aaron Cheng; Larry Kessler; David H Au; David R Flum
Journal:  Ann Thorac Surg       Date:  2014-10-03       Impact factor: 4.330

5.  Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer.

Authors:  Keisuke Asakura; Yukihiro Yoshida; Hiroyuki Sakurai; Kazuo Nakagawa; Noriko Motoi; Shun-Ichi Watanabe
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

6.  Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer.

Authors:  Haitao Zhou; Xiaozheng Kang; Liang Dai; Wanpu Yan; Yongbo Yang; Yao Lin; Ke-Neng Chen
Journal:  Thorac Cancer       Date:  2018-06-19       Impact factor: 3.500

7.  Survival after wedge resection versus lobectomy for stage IA second primary NSCLC with previous lung cancer-directed surgery.

Authors:  Congkuan Song; Zilong Lu; Donghang Li; Shize Pan; Ning Li; Qing Geng
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

Review 8.  [Diagnosis and Treatment for Multiple Primary Lung Cancer].

Authors:  Lijie Tan; Jun Yin
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.